MedPath

GENSPERA INC

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

8

Active:1
Completed:5

Trial Phases

2 Phases

Phase 1:2
Phase 2:6

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials

Phase 2
6 (75.0%)
Phase 1
2 (25.0%)

Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma

Phase 2
Withdrawn
Conditions
Glioblastoma
Interventions
First Posted Date
2016-08-23
Last Posted Date
2017-02-24
Lead Sponsor
GenSpera, Inc.
Registration Number
NCT02876003
Locations
🇺🇸

John Wayne Cancer Institute, Santa Monica, California, United States

Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA

Phase 2
Completed
Conditions
Clear Cell Renal Cell Carcinoma
Interventions
First Posted Date
2015-11-18
Last Posted Date
2017-02-24
Lead Sponsor
GenSpera, Inc.
Target Recruit Count
2
Registration Number
NCT02607553
Locations
🇺🇸

University of Texas Health Science Center, Houston, Houston, Texas, United States

G-202 in the Neoadjuvant Setting Followed by Radical Prostatectomy in Patients With Prostate Cancer

Phase 2
Completed
Conditions
Prostatic Neoplasms
Interventions
First Posted Date
2015-03-06
Last Posted Date
2017-02-24
Lead Sponsor
GenSpera, Inc.
Target Recruit Count
1
Registration Number
NCT02381236
Locations
🇺🇸

University of Texas Health Sciences Center, Houston, Texas, United States

Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma

Phase 2
Completed
Conditions
Glioblastoma Multiforme
Interventions
First Posted Date
2014-02-20
Last Posted Date
2024-05-21
Lead Sponsor
GenSpera, Inc.
Target Recruit Count
26
Registration Number
NCT02067156
Locations
🇺🇸

University of California, San Diego Moores Cancer Center, La Jolla, California, United States

Study of G-202 (Mipsagargin) as Second-Line Therapy Following Sorafenib in Hepatocellular Carcinoma

Phase 2
Completed
Conditions
Advanced Adult Hepatocellular Carcinoma
Interventions
First Posted Date
2013-01-29
Last Posted Date
2016-08-23
Lead Sponsor
GenSpera, Inc.
Target Recruit Count
25
Registration Number
NCT01777594
Locations
🇺🇸

Mary Crowley Cancer Research Center, Dallas, Texas, United States

🇺🇸

Oncology Consultants, PA, Houston, Texas, United States

🇺🇸

University of Texas Health Sciences Center at Houston, Memorial Hermann Cancer Center, Houston, Texas, United States

and more 1 locations
  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.